Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study.

Autor:	Skertich NJ; Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612,USA., Chu F; Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612,USA., Tarhoni IA; Department of Pathology, Rush University Medical Center, Chicago, IL 60612, USA.; Department of Cell & Molecular Medicine, Rush University Medical Center, Chicago, IL 60612, USA., Szajek S; Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612,USA., Borgia JA; Department of Pathology, Rush University Medical Center, Chicago, IL 60612, USA.; Department of Cell & Molecular Medicine, Rush University Medical Center, Chicago, IL 60612, USA., Madonna MB; Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612,USA.
Jazyk:	angličtina
Zdroj:	Surgery open science [Surg Open Sci] 2021 Jul 14; Vol. 6, pp. 10-14. Date of Electronic Publication: 2021 Jul 14 (Print Publication: 2021).
DOI:	10.1016/j.sopen.2021.07.001
Abstrakt:	Background: Inhibition of the programmed death ligand 1, programmed death 1 pathway has been successfully used for treatment of multiple advanced adult cancers. However, its use in pediatric osteosarcoma is still in its infancy. In this study, we investigated programmed death ligand 1 and other checkpoint molecules' expression to determine the potential usefulness as targets for drug therapy. Methods: We incubated human wild-type osteosarcoma cells with incremental concentrations of doxorubicin to create a doxorubicin-resistant cell line. Matrigel in vitro invasion assays were used to compare invasiveness. Comparative programmed death ligand 1 expression was evaluated by Western blot assays. An immuno-oncology checkpoint protein panel was used to compare concentrations of 16 other checkpoint molecules. Chi-square tests and Wilcoxon rank-sum tests were used to determine significant differences. Results: A doxorubicin-resistant cell line was successfully created and was significantly more invasive than wild-type cells (0.47 vs 0.07, P < .001). On Western blot assay, doxorubicin-resistant but not wild-type cells expressed programmed death ligand 1. Doxorubicin-resistant cells had significantly higher levels of T-cell immunoglobulin-3 and cluster of differentiation 86 and higher cluster of differentiation 27, cluster of differentiation 40, lymphocyte-activation gene-3, cluster of differentiation 80, programmed death ligand 1, programmed death ligand 2, and inducible T-cell costimulatory expression than wild-type cells. Both lines expressed B- and T-lymphocyte attenuator, cluster of differentiation 28, herpesvirus entry mediator, and programmed death 1. Herpesvirus entry mediator, cluster of differentiation 40, and programmed death ligand 2 were also present in the culture media of both cell lines. Conclusion: Doxorubicin-resistant osteosarcoma seems to express higher programmed death ligand 1 than nonresistant wild-type cells. Benchmarking checkpoint molecules may provide the basis for future studies that elucidate pathways of drug resistance and tumor metastasis, biomarkers for cancer prognosis or recurrence, and future targets for directed drug therapy. (© 2021 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu